@article {SelcukA621, author = {I Selcuk and M Lanner and A Pletnev and D Vlachos and T Nikolova and D Lindquist and K Zalewski}, title = {EP1210 Follow-up in gynecologic malignancies, correspondence with ESGO Guidelines- preliminary result of ENYGO survey}, volume = {29}, number = {Suppl 4}, pages = {A621--A623}, year = {2019}, doi = {10.1136/ijgc-2019-ESGO.1247}, publisher = {BMJ Specialist Journals}, abstract = {Introduction/Background To identify the follow-up strategies of gynecologic malignancies across Europe and compare the correspondence with ESGO Guidelines.Methodology In 2019, a web-based survey was sent to the National Representatives of European Network of Young Gynae-Oncologists (2017{\textendash}2019). The questionnaire consists of the questions related with vulvar cancer, cervical cancer, endometrial cancer and ovarian cancer.Results A total of 15/31 (48.3\%) National Representatives responded the survey. Despite having a national guideline (\>50\%), the topic of follow-up was missing in some countries. The follow-up was mainly led by clinicians and performed by gynecologic oncology team (table 1). For each malignancy, gynecologic examination is performed at every visit. Responders stated that Pap-test is routinely performed during the follow-up of cervical cancer 8/8 (100.0\%), additionally in endometrial cancer 4/7 (57.1\%) of responders perform routine Pap-test. Serum Ca-125 level is never routinely preferred during the follow-up of endometrial cancer, however serum Ca-125 is mostly preferred routinely for ovarian cancer. Complete blood count-biochemical tests and chest X-ray are not routine tests to consider at every visit. Routine imaging is mostly preferred for ovarian cancer and computed tomography is the most common imaging technique in case of a suspicion of recurrence except vulvar cancer in which magnetic resonance imaging is preferred (table 2).Conclusion This preliminary results indicated that follow-up periods are similar with ESGO Guidelines. One of the major differences is that cytology is not recommended after radical/simple hysterectomy or chemoradiation in cervical cancer and the other one is serum Ca-125 is not a reliable marker in non-High grade serous carcinoma of the ovary. ESGO Guidelines generally don{\textquoteright}t recommend routine imaging unless a clinically indicated situation. Finally, these preliminary results showed that majority of the responses are similar with ESGO Guidelines.Disclosure Nothing to discloseView this table:Abstract EP1210 Table 1 Follow-up methods and periods for vulvar, cervical, endometrial and ovarian cancerView this table:Abstract EP1210 Table 2 Performed procedures at every visit for vulvar, cervical, endometrial and ovarian cancer}, issn = {1048-891X}, URL = {https://ijgc.bmj.com/content/29/Suppl_4/A621.3}, eprint = {https://ijgc.bmj.com/content/29/Suppl_4/A621.3.full.pdf}, journal = {International Journal of Gynecologic Cancer} }